UK Markets close in 7 hrs 23 mins

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.2051+0.0001 (+0.05%)
At close: 03:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 3200.0000
52-week low 30.1810
50-day moving average 35.8279
200-day moving average 320.5597

Share statistics

Avg vol (3-month) 385.42k
Avg vol (10-day) 3394.94k
Shares outstanding 552.04M
Implied shares outstanding 6N/A
Float 834.05M
% held by insiders 142.20%
% held by institutions 126.23%
Shares short (14 Sept 2022) 41.02M
Short ratio (14 Sept 2022) 41.9
Short % of float (14 Sept 2022) 42.18%
Short % of shares outstanding (14 Sept 2022) 41.74%
Shares short (prior month 14 Aug 2022) 41.92M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:2
Last split date 325 Mar 2021

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-35.30%
Return on equity (ttm)-427.17%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -25.72M
Net income avi to common (ttm)-106.73M
Diluted EPS (ttm)-0.4470
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)19.41M
Total cash per share (mrq)0.33
Total debt (mrq)2.82M
Total debt/equity (mrq)19.10
Current ratio (mrq)3.08
Book value per share (mrq)0.25

Cash flow statement

Operating cash flow (ttm)-22.68M
Levered free cash flow (ttm)-10.93M